Exploring the effect of iron ligand interactions on iron uptake pathways and inflammatory response in human cell lines
Year: 2025
Type: article
Abstract: Iron supplementation is essential for treatment of iron deficiency anemia, the most common nutritional disorder worldwide (WHO, 2021). While oral iron supplementation remains the first-line therapy, its use is not without risk, particularly for individuals with pre-existing gastrointestinal conditions such as inflammatory bowel disease (IBD) or Crohn’s disease, where pro-inflammatory responses to certain iron formulations could exacerbate the condition. Understanding how the iron-ligand interactions of oral iron compounds influence their inflammatory potential is critical for optimizing treatment safety and efficacy. Investigating six iron chelates and six iron salts demonstrated that all iron chelates significantly induced the MAPK signaling pathway, as evidenced by elevated amphiregulin levels (Paper I). The two most chemically stable polydentate chelates, ferric EDTA and ferric pyrophosphate, upregulated amphiregulin and IGFr1 at physiologically relevant concentrations ([Fe]=0.05 mM). This effect was not observed with any of the tested iron salts. Ferric pyrophosphate also induced the pro-inflammatory enzyme cyclooxygenase-2 (COX-2) and stimulated production of interleukin-6, indicating the most pronounced pro-inflammatory profile among the tested compounds. To further investigate these inflammatory responses, we examined COX-2 and lipooxygenase-5 (LOX-5) levels in intestinal cell lines derived from both male and female donors (Paper III). The results demonstrated that solubility and the particle size, formed in cellular medium (pH 7.4) supplemented with ferric pyrophosphate or ferrous fumarate was associated with elevated COX-2 levels in most of the tested cell lines. The fully soluble ferric EDTA did not elicit such response. Importantly, these effects occurred independently of ferritin accumulation, suggesting that inflammatory signaling was driven by the formed particles, rather than by total cellular iron load. In a mechanistic follow-up study (Paper II), ferrous fumarate was found to utilize both the DMT1 transporter and clathrin-mediated endocytosis for cellular uptake, challenging the common view that the intestinal uptake of iron from iron salts is tightly regulated by means of being transported by the DMT1-mediated pathway. Cellular uptake of iron from ferrous sulfate and ferric EDTA was confirmed to be independent of clathrin-mediated endocytosis. In a gut-liver axis model (Caco-2/HepG2), ferric pyrophosphate treatment (0.2 mM) induced key MAPK/ERK pathway activators, including the IFN-γ receptor, EGF, and CDKN1A, which was further validated in Caco-2 monocultures exposed to commercially available ferric pyrophosphate (0.4 mM), where IL-6 production was observed. This response was not observed in cells treated with a nanoparticulate iron, Iron hydroxide adipate tartrate (IHAT). In conclusion, this thesis demonstrates that the iron-ligand interactions are critical determinants of both the intestinal uptake route and downstream inflammatory effects in intestinal cell models. These insights highlight the need to carefully consider the choice of iron ligand, when designing an iron supplements in order to minimize adverse effects while ensuring therapeutic efficacy.
Author: Tarczykowska, Agata
Institution: Chalmers University of Technology
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: iron supplementation, iron chelates, iron salts, inflammation, MAPK signaling, amphiregulin, IGF-1 receptor, cyclooxygenase-2, interleukin-6, DMT1, clathrin-mediated endocytosis, ferric EDTA, ferric pyrophosphate, ferrous fumarate, ferrous sulfate, iron deficiency anemia, inflammatory bowel disease, gut-liver axis
Open Access status: green
OpenAlex ID: W7210473073
